Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma

Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting

Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL

Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting 

Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab 

Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates

Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection